Co-administration of cyclosporin enables oral therapy with paclitaxel

Lancet

Volumn 352, Issue 9124, 1998, Pages 285-

  Meerum Terwogt, Jetske M ^a,b   Beijnen, Jos H ^b   Ten Bokkel Huinink, Wim W ^b   Rosing, Hilde ^b   Schellens, Jan H M ^b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CREMOPHOR; CYCLOSPORIN; DRUG VEHICLE; IMMUNOSUPPRESSIVE AGENT; PACLITAXEL;

ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032566193     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(98)24030-x     Document Type: Article

References (5)

1. 1 Borst P, Schinkel AH. Genetic dissociation of the function of mammalian P-glycoproteins. Trends Genet 1997; 13: 217-22.
2. 2 Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
3. 3 Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci 1997; 4: 2031-35.
4. 4 van Asperen J, van Tellingen O, Sparreboom A, et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 1997; 76: 1181-83.
5. 5 Huizing MT, Giaccone G, van Warmerdam LJC, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and sequencing study in patients with non-small cell lung cancer. J Clin Oncol 1997; 15: 317-29.